IART - Comprehensive Filing Intelligence

FY 2025•10-K•Filed Feb 26, 2026

4.0/10

Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

The company experienced a significant net loss in 2025, largely due to a $511.4 million goodwill impairment charge, indicating potential issues with past acquisitions.. The company faces ongoing regulatory scrutiny from the FDA related to quality systems, with specific warning letters and observations impacting operations and potentially delaying PMA approvals.. Significant contingent liabilities exist from multiple acquisitions, with potential payouts up to $90 million tied to future revenue and regulatory approvals.. Significant goodwill impairment charge ($511.4M) affecting all segments.

Top Concerns

!Gross margins declined significantly in 2025 due to quality and operational issues, higher manufacturing costs, and tariffs, raising concerns about profitability.
!Operating cash flow decreased substantially in 2025, impacted by quality issues and rising inventory levels, signaling potential weaknesses in cash generation.
!Significant goodwill impairment charge ($511.4 million) in Q2 2025, driven by stock price decrease and economic uncertainty.
!Increased allowance for doubtful accounts receivable ($2,351M in 2025 from $1,728M in 2024, an increase of $623M or 36%).
!Significant contingent liabilities exist from multiple acquisitions, with potential payouts up to $90 million tied to future revenue and regulatory approvals.

Top Positives

+Management expresses confidence in near-term liquidity but acknowledges significant uncertainties related to tariffs, trade policies, and ongoing operational improvements.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

6.0/10

Management tone is balanced with focus on timing of the acclarent acquisition.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

5.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is moderate with $260.15 million in identified exposure.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

3.0/10

Overall risk profile shows competitive landscape as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

4.0/10

Segment health analysis shows Codman Specialty Surgical as strongest performer while Tissue Technologies lags.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.